Arcadia Biosciences Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income (loss) | $2,599 | $(2,423) |
| Adjustments to reconcile net income to cash used in operating activities: | ||
| Change in fair value of common stock warrant and option liabilities | (1,862) | (593) |
| Change in fair value of contingent consideration | (1,000) | — |
| Depreciation | 13 | 51 |
| Lease amortization | 104 | 177 |
| Amortization of note receivable | (69) | — |
| Loss on sale of property and equipment | — | 2 |
| Gain on sale of intangible assets | (750) | — |
| Stock-based compensation | 78 | 138 |
| Impairment of property and equipment | — | 36 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and other receivables | (193) | (246) |
| Inventories | (381) | 303 |
| Prepaid expenses and other current assets | 205 | 275 |
| Accounts payable and accrued expenses | (213) | (678) |
| Amounts due to related parties | — | 17 |
| Operating lease liabilities | (119) | (269) |
| Net cash used in operating activities | (1,588) | (3,210) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sale of intangible assets | 500 | — |
| Proceeds from sale of property and equipment | — | 17 |
| Purchases of property and equipment | — | (13) |
| Net cash provided by investing activities | 500 | 4 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from ESPP purchases | 5 | 5 |
| Net cash provided by financing activities | 5 | 5 |
| Net decrease in cash and cash equivalents | (1,083) | (3,201) |
| Cash and cash equivalents — beginning of period | 4,242 | 6,518 |
| Cash and cash equivalents — end of period | $3,159 | $3,317 |
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
| Proceeds from sale of property and equipment in accounts receivable and other receivables | $— | $12 |
| Purchases of property and equipment in accounts payable and accrued expenses | $— | $13 |
| Right of use assets obtained in exchange for new operating lease liabilities | $— | $86 |
| Proceeds from sale of intangible assets in accounts receivable and other receivables | $250 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.